Ankerst J, Fäldt R, Nilsson PG, Flodgren P, Sjögren HO. Complete remission in a patient with acute myelogenous leukemia treated with leukocyte alpha-interferon and cimetidine.
Cancer Immunol Immunother 1984;
17:69-71. [PMID:
6587932 PMCID:
PMC11039209 DOI:
10.1007/bf00205501]
[Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/1984] [Accepted: 03/06/1984] [Indexed: 01/20/2023]
Abstract
A 76-year-old woman with acute myelogenous leukemia with approximately 65% myeloblasts on bone marrow examination was treated daily with a combination of 4 megaU of leukocyte interferon IM and 1,000 mg cimetidine PO. During therapy there was a gradual decrease of bone marrow myeloblasts down to 9% and a normalization of peripheral white blood cells. The treatment was discontinued after 6 weeks because of increasing fatigue and anorexia. The general condition improved greatly during the following weeks and the patient entered complete remission, which has continued for 6 months so far. In the course of therapy there was a gradual appearance of antibodies showing a selective binding capacity to autochthonous leukemic cells with no tendency to increased binding to remission cells. The aim of this report is to stimulate a further evaluation of this form of therapy in additional AML patients whenever this might be justified as an alternative to conventional chemotherapy.
Collapse